Benefits and Pitfalls of Plasmin Derivatives Application for Thrombolysis: A Narrative Review

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F24%3A00081606" target="_blank" >RIV/00159816:_____/24:00081606 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/24:00139983
Result on the web
<a href="https://biomedgrid.com/pdf/AJBSR.MS.ID.003101.pdf" target="_blank" >https://biomedgrid.com/pdf/AJBSR.MS.ID.003101.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.34297/AJBSR.2024.23.003101" target="_blank" >10.34297/AJBSR.2024.23.003101</a>

Result language
angličtina
Original language name
Benefits and Pitfalls of Plasmin Derivatives Application for Thrombolysis: A Narrative Review
Original language description
Cardio- and cerebrovascular thrombosis is a serious pathology with the highest lethality and disability rates in the world. The current thrombolytic therapy is mainly based on plasminogen activators, such as streptokinase, urokinase and tissue plasminogen activator. As soon as their target is ad hoc plasminogen activation, an addressed plasmin(ogen) delivery to a clot could have at least the same efficiency. Here we present in a form of narrative review thrombolytic potential of plasmin(ogen) and its derivatives, which in some experiments outperformed approved plasminogen activators. We believe that these factors will find their niches in clinical thrombolytic therapy in the near future.
Czech name
—
Czech description
—

Project
<a href="/en/project/NU21-08-00510" target="_blank" >NU21-08-00510: Biocompatible nanoparticles tailored as targeted drug delivery systems and theranostics for treatment of stroke</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)